The pharmaceutical industry has long claimed that the government trying to negotiate better prices for Medicare, health are for the elderly, takes away from new drug research and development. But a new report by the watchdog group Public Citizen and Protect our Care reveals […]
Dr. Sidney Wolfe of Public Citizen leaves a proud legacy of unearthing pharmaceutical industry dangers and corruption
The following is a news commentary. I was a reporter at CBS News 20+ year ago when I was assigned my first stories on medical safety issues and government-pharmaceutical industry corruption for the CBS Evening News and I met Dr.
News reports indicate that Dan Ziegler, a Washington lobbyist counting among his clients PhRMA, Pfizer, Merck, Sanofi, Eli Lilly and Amgen, will join House Speaker Mike Johnson’s office as policy director. Public Citizen, a nonprofit consumer advocacy organization that works
Public Citizen’s Health Research Group wants the FDA to deny speeded up approval of a new gene therapy treatment. The advocacy group states that the treatment, SRP-9001 (Sarepta Therapeutics) for ambulatory Duchenne muscular dystrophy (DMD), intended for children aged four
Gabapentin has quietly become one of the most widely-prescribed drugs in America, and some say that could spell big trouble. Michael Abrams of Public Citizen explains why, as neurologist Dr. Brian Callaghan offers a counterpoint.
The following is an excerpt from the DisInformation Chronicle written by Paul D. Thacker. New documents further detail the hundreds of thousands of dollars in federal funds diverted to set up the Global Virome Project, an organization now headed by Dennis
It’s estimated that about six million people in the U.S. have the dreaded form of dementia known as Alzheimer’s disease. The search for a cure has fallen frustratingly short. Now, one pharmaceutical company says a cure, at least for early
Is the first true cure for early Alzheimer’s disease on the horizon? The makers of still unapproved drug aducanumab say — maybe. But there’s a lot of controversy surrounding the promise. Watchdogs say there’s little to no evidence the drug